Expert suggestion for osteoporosis management during the recent COVID-19 pandemic
Received date: 2022-05-27
Online published: 2022-04-25
中华医学会内分泌学分会 . 新型冠状病毒肺炎疫情下骨质疏松症管理专家建议[J]. 诊断学理论与实践, 2022 , 21(02) : 133 -135 . DOI: 10.16150/j.1671-2870.2022.02.005
Osteoporosis is a chronic condition that reflects reduced bone strength and increased risk for fracture. As a chronic disease, osteoporosis generally requires sustained medical intervention to reduce the risks for bone loss, impaired bone integrity and fractures. The coronavirus disease 2019(COVID-19) pandemic has brought the unprecedented harmful effects on medical service,such as the cessation of osteoporosis therapies might be associated with an increased harm for bone health. The present expert suggestion provides recommendation for the management of osteoporotic patient during COVID-19, to help them safely return to routine clinical management.
| [1] | Lv H, Zhang Q, Yin Y, et al. Epidemiologic characteristics of traumatic fractures during the outbreak of coronavirus disease 2019 (COVID-19) in China: A retrospective & comparative multi-center study[J]. Injury,2020, 51(8):1698-1704. |
| [2] | 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017)[J]. 中华内分泌代谢杂志, 2017, 33(10):890-913. |
| [2] | Osteoporosis and bone mineral Disease Branch of Chinese Medical Association. Diagnosis and treatment guidelines for primary osteoporosis(2017)[J]. Chin J Endocrinol Metab, 2017, 33(10):890-913. |
| [3] | Mitchell F. Vitamin-D and COVID-19: do deficient risk a poorer outcome?[J]. Lancet Diabetes Endocrinol, 2020, 8(7):570. |
| [4] | 中国营养学会骨营养与健康分会, 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症患者的营养和运动管理专家共识[J]. 中华内分泌代谢杂志, 2020, 36(8):643-653. |
| [4] | Bone nutrition and health branch of Chinese Nutrition Society, Osteoporosis and bone mineral Disease Branch of Chinese Medical Association. Expert consensus on nutrition and exercise management of patients with primary osteoporosis[J]. Chin J Endocrinol Metab, 2020, 36(8):643-653. |
| [5] | 杨嫣琼, 张巧, 彭年春, 等. 睡眠时长、入睡时间与绝经后女性骨质疏松风险的相关性研究[J]. 中华内分泌代谢杂志, 2020, 36(11):949-955. |
| [5] | Yang YQ, Zhang Q, Peng NC, et al. Study on the relationship between sleep duration, sleep time and the risk of osteoporosis in postmenopausal women[J]. Chin J Endocrinol Metab, 2020, 36(11):949-955. |
| [6] | Saag K, Lindsay R, Kriegman A, et al. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density[J]. Bone, 2007, 40(5):1238-1243. |
| [7] | Rossini M, Adami S, Viapiana O, et al. Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration[J]. J Bone Miner Res, 2012, 27(1):227-230. |
| [8] | Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial[J]. Lancet, 2020, 395(10240):1845-1854. |
| [9] | Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine[J]. N Engl J Med, 2021, 384(5):403-416. |
| [10] | Reid IR, Gamble GD, Mesenbrink P, et al. Characterization of and risk factors for the acute-phase response after zoledronic acid[J]. J Clin Endocrinol Metab, 2010, 95(9):4380-4387. |
| [11] | Blanch-Rubió J, Soldevila-Domenech N, Tío L, et al. Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions[J]. Aging (Albany NY), 2020, 12(20):19923-19937. |
| [12] | Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension[J]. Lancet Diabetes Endocrinol, 2017, 5(7):513-523. |
/
| 〈 |
|
〉 |
